好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation: Two Siblings with A Novel Mutation in The DARS2 Gene.
Neuromuscular and Clinical Neurophysiology (EMG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
12-044

 Reporting a novel mutation in the DARS2 gene in two siblings with Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL). 

LBSL is a rare autosomal recessive hereditary disease, characterized by slowly progressive pyramidal and cerebellar dysfunction, often with concomitant dorsal column dysfunction. Here we report two siblings with LBSL and a novel c.1192-2A>G mutation in the DARS2 gene.

 

Case report 

Two siblings, a 49-year-old male and 42-year-old female carried a diagnosis of Charcot Marie Tooth disease (CMT), syringomyelia, motor neuropathy and leukodystrophy of unknown cause. During the early childhood, they both developed bilateral foot drop. Their symptoms slowly progressed and were wheelchair bound at 18 years of age.  Neurological examination was significant for areflexia in the lower limbs more than the upper limbs. Distal lower extremity muscles atrophy along with contractures of the fingers and foot are noted. There was also decreased pinprick, proprioception sensation in a grading fashion bilaterally in the legs along with absent vibration sensation below the knees. Because their clinical presentation was atypical for CMT, an MRI was obtained which showed bilateral symmetrical T2 hyperintensities involving the supratentorial white matter predominantly in the periventricular region, cerebellar peduncles, and brain stem. In addition, there was confluent diffuse restriction abnormalities in the cervical and thoracic spinal cord involving the dorsal columns, and the lateral corticospinal tracts. All these imaging findings were characteristic of LBSL. Genetic analysis identified two heterozygous variants in DARS2: c.228-15C>A and a novel variant c.1192-2A>G that is predicted to be pathogenic in both the patients. 

In a patient with atypical history and presentation of Charcot Marie Tooth disease (CMT), it is important to have a high degree of suspicion for LBSL. 
Authors/Disclosures
Anudeep Yelam, MD
PRESENTER
Dr. yelam has nothing to disclose.
Elanagan Nagarajan, MD Dr. Nagarajan has nothing to disclose.
Miguel Chuquilin Arista, MD, FAAN Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item writer with 好色先生. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item Writer with 好色先生. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item Writer with 好色先生. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Item reviewer with National Board of Medical Examiners. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Southeast regional advisory board with Argenx. Dr. Chuquilin Arista has received personal compensation in the range of $500-$4,999 for serving as a Focus group with Alexion. Dr. Chuquilin Arista has received personal compensation in the range of $0-$499 for serving as a Speaker with Periodic Paralysis Association.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.